The global biopharmaceutical industry continues to expand at rapid rate in recent years with world biological drugs market expected to reach $178.4bn in 2017. The emergence of mAbs has produced significant breakthroughs in the treatment of cancer and autoimmune diseases. Led by development of monoclonal antibodies (mAbs), the biologics industry has witnessed phenomenal growth in the past 10 years. In 2015, seven of the top 10 best-selling drugs were biologics, including six mAbs. In the first half of 2016, the sales of 37 mAb drug totaled $42.3 billion. Immune-oncology mAbs such as Keytruda (pembrolizumab) and recently approved Bavencio(avelumab) and an exciting immuno-oncology pipeline are set to drive the growth of antibody therapeutics in the years to come.
According to Reuters’ reports, the biologics industry in China is estimated to be the fastest growing market in the world. Driven by innovative drugs R&D, improved speed and transparency of submission review, strategies and reforms for better quality, MAH systems etc., China now is the second-highest number of biosimilars in development after the United States. As of April 2016, it is estimated that 27 companies are developing a biosimilar to Humira (adalimumab). Besides, the Chinese government created mega research grants with an average $1 billion per year to support innovative biologics program such as PD-1 and ADCs. In December 2015, China’s very first anti-PD-1 antibody by Shanghai Junshi Biosciences was approved for clinical trials by the CFDA. Throughout China an additional 15 PD-1 or PDL-1 programs are in preclinical development.
Riding on the success of the meeting last year, Biologics Innovation and Frontier Technology (BIFT 2017) is the definitive conference in China for receiving first-hand information on the current international status of the Biopharmaceutical industry and China’s biopharmaceutical opportunities, bringing together decision makers across C level management, R&D and Manufacturing in the realms of biologic drugs, biosimilars, biotech and Immuno-oncology sectors.
This two day interactive meeting will provide you the opportunity to take home cutting edge strategies, case study examples, regulatory guidelines with rich information on the latest innovations, strategy, pipeline, partnership and exciting candidates from leading biopharmas in China; case studies on cell lines and process development, scale-up and downstream innovations, single-use technology; evaluation and quality of biosimilars, frontier technology in biologics development etc. We welcome you to the meeting to establish and renew partnerships to help develop new products, acquire new process technologies, and establish new contract manufacturing relationships.